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Abstract 25 
The objective of this investigation was to evaluate phenobarbital transdermal 26 
delivery for possible use in paediatric care. In vitro experiments were performed 27 
using intact pig skin and barriers from which the stratum corneum had been stripped 28 
to different extents to model the less resistant skin of premature babies. Cathodal 29 
iontophoretic delivery of phenobarbital was superior to anodal transport and 30 
optimised delivery conditions were achieved by reduction of competing co-ion 31 
presence in the drug formulation. Phenobarbital transport across intact or partially 32 
compromised skin was controlled by iontophoresis which was more efficient than 33 
passive diffusion. Across highly compromised skin, however, passive diffusion 34 
increased drastically and iontophoretic control was lost. Overall, this study 35 
demonstrates the feasibility of phenobarbital transdermal delivery for paediatric 36 
patients. 37 
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1. Introduction 42 
Phenobarbital is a barbiturate drug used in the treatment of different forms of 43 
paediatric epilepsy and status epilepticus (BNF for children, 2011) being the first-line 44 
choice to control neonatal seizures (Lehr, 2005, Blume, 2009, Ouvrier, 1982). It is 45 
also used to treat neonatal abstinence syndrome both in the case of sedative-46 
hypnotic withdrawal and as an adjunct therapy to treat opiate withdrawal symptoms 47 
(Bio, 2011, Finnegan, 2005, Osborn, 2010). Due to developmental changes in 48 
children, the pharmacokinetics of phenobarbital are highly variable in this 49 
population; doses are, therefore, titrated according to the individual’s response for 50 
adequate seizure control while avoiding, at the same time, adverse effects due to 51 
supra-optimal levels (BNF for children 2011, Finnegan, 2005, Heimann, 1977, Lehr, 52 
2005, Touw, 2000). The target therapeutic plasma concentrations are set between 53 
40 and 180 µmol.mL-1 depending on the application envisaged (Bio, 2011, Finnegan, 54 
2005, Lehr, 2005, Touw, 2000). Heimann (1977) found that the elimination half-life 55 
of phenobarbital in mature neonates (118 ± 16 h) is significantly longer than that in 56 
infants of 2-12 months (63 ± 5h) and in children aged 2-5 years (68 ± 3h). Touw 57 
(2000) found that the elimination half-life varied between 48 and 147 h for a group 58 
of 19 term and preterm neonates. Phenobarbital clearance is slowest for newborns, 59 
increasing rapidly during the first two weeks of life and reaching a peak at 6-12 60 
months. On the other hand, the total clearance normalized per kg body weight 61 
appears to decrease with increasing maturity (Touw, 2000, Lehr 2005). The average 62 
clearance of phenobarbital in neonates is about 4.3 mL.h-1.kg-1 (Touw, 2000) 63 
whereas, for older children, a mean value of approximately 8 mL.h-1.kg-1 is observed 64 
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(Botha, 1995, Heimann, 1977, Winter, 2010). Phenobarbital distribution volume 65 
decreases with age and with gestational age; Touw (2000) reported a mean volume 66 
of distribution of 0.71 ± 0.21 L.kg-1 for term and preterm neonates. Heimann (1977) 67 
used a two-compartmental model to describe phenobarbital kinetics in children of 68 
several age groups, from term neonates up to 5 years old, and found a modest age 69 
dependency for both the volume of distribution in the steady-state and the volume 70 
of the central compartment; the values reported for Vss ranged from 0.85 ± 0.06 to 71 
0.67±0.07 L.kg-1. 72 
Phenobarbital is well absorbed orally (Winter, 2010); however, tablets are not 73 
suitable for neonates and young children and the only approved oral alternative 74 
described in the BNF (BNF for children, 2011) contains 38% ethanol. Regular 75 
administration of this elixir may cause alcohol toxicity, especially in neonates. As 76 
consequence, extemporaneous formulations, including suspensions from crushed 77 
tablets, are sometimes prepared (Cober, 2007, Colquhoun-Flannery 1992). Slow 78 
intravenous injections are also frequently used, but care must be taken to dilute the 79 
parenteral formulation (200 mg.mL-1 phenobarbital in 90% propylene glycol) to 80 
provide suitable doses for young infants and children and to avoid accumulation of 81 
the cosolvent (Allagaert, 2010, BNF for children 2011). 82 
Passive transdermal delivery of phenobarbital has been suggested as an 83 
alternative route of administration (Bonina, 1993). In this earlier in vitro study, drug 84 
flux across excised skin from premature infants (29 – 35 weeks gestational age) was 85 
approximately 4-fold greater (0.4 ± 0.13 µg.h-1.cm-2) than that (0.1 ± 0.02 µg.h-1.cm-2) 86 
through either adult or full-term (37 – 40 weeks gestational age) skin. In general, 87 
fluxes were inversely related to the gestational age of the donor. It was estimated 88 
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that a 25 cm2 transdermal patch would be sufficient to provide an average steady-89 
state plasma concentration of 3.2 mg.L-1 (14 µM) for a 1 kg neonate. However, the 90 
feasibility of the approach employed may be questioned as the vehicle used in this 91 
work was pure ethanol which is known to be toxic to preterm newborns when 92 
absorbed across the skin from cleaning products (Harpin, 1982). Further, the total 93 
skin surface area of a neonate varies between 0.03 and 0.25 m2 depending on 94 
gestational age (Touw, 2000). While there are no guidelines concerning the 95 
maximum acceptable size of a transdermal patch for neonatal use, values in the 96 
range of 1-10 cm2 would be consistent with current usage in adults: for these 97 
individuals, total skin area is ~ 2 m2, while largest patches in use are in the order of 98 
50 cm2. Finally, the systemic concentration achievable (14 µM) is lower than the 99 
recommended target for paediatric patients (40 – 180 µM). 100 
Here, an optimised approach to the delivery of phenobarbital across both intact 101 
and premature skin is proposed. Using iontophoresis as a physical enhancement 102 
method, improved delivery rates of the drug are achieved compared to passive 103 
diffusion suggesting that smaller patch sizes can be used to attain therapeutic 104 
systemic levels. With iontophoresis, the much more water-soluble sodium salt of 105 
phenobarbital is preferred eliminating the need for incorporation of co-solvents 106 
(such as ethanol) in the topical formulation. The aqueous solubility of sodium 107 
phenobarbital (molecular weight = 254.2 Da) is 1 g/mL, approximately 1000-fold 108 
greater than that of the free acid. Intact and premature neonatal skin barriers were 109 
modelled in vitro using pig skin, from which stratum-corneum was differentially tape-110 
stripped as previously described (Sekkat, 2004a, 2004b). 111 
 112 
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2. Materials and methods 115 
2.1 Chemicals 116 
Sodium phenobarbital (PHEN), silver wire (99.99%), silver chloride (99.999%), 117 
sodium hydroxide pellets, and NaOH 50% solution (ion chromatography eluent 118 
grade) were purchased from Sigma Aldrich (Gillingham, UK). Potassium dihydrogen 119 
phosphate, HEPES (4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) and 120 
sodium chloride were obtained from Acros (Geel, Belgium). Acetonitrile and 121 
hydrochloric acid were provided by Fisher Scientific (Loughborough, UK). All reagents 122 
were at least analytical grade and deionised water (resistivity ≥ 18.2 MΩ.cm, 123 
Barnsted Nanopure DiamondTM, Dubuque, IA) was used for the preparation of all 124 
solutions. 125 
2.2 Skin 126 
Fresh pig skin was obtained from a local slaughterhouse, cleaned under cold 127 
running water, and stored in a refrigerator until the following day. Abdominal skin 128 
was dermatomed (Zimmer™ Electric Dermatome, Dover, Ohio) to a nominal 129 
thickness of 750 µm, cut into (10 x 10 cm2) pieces, wrapped individually in Parafilm™, 130 
and then kept in a freezer (-20 °C) until use. Prior to the experiments, the skin was 131 
thawed at room temperature for 30 minutes and excess hair was cut with scissors. 132 
The large piece of skin was then cut into 4 portions. One served as representative of 133 
the intact skin barriers while the others were subjected a tape-stripping procedure 134 
to create different degrees of compromised skin. The intact barriers were 135 
characterized by transepidermal water loss (TEWL) measurements (AquaFlux AF-102, 136 
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Biox Systems Ltd., London, UK) of 9.0 ± 1.7 g.m-2.h-1. The three other pieces of skin 137 
were repeatedly tape-stripped (2 x 2 cm, Scotch Book Tape, 3M, St. Paul, MN) to 138 
progressively remove the stratum corneum. A 1.5 x 1.5 cm2 template was affixed 139 
onto the skin before the stripping procedure started to ensure the removal of 140 
stratum corneum was from the same location. Periodic measurement of TEWL 141 
allowed the degree of barrier compromise to be quantified and full barrier 142 
impairment was defined when the removal of three consecutive tape strips did not 143 
alter TEWL. The number of tape strips required to produce a fully compromised 144 
barrier varied between 13 and 23. The second and third pieces of skin were tape-145 
stripped until TEWL reached values of between 20-40% and 60-80%, respectively, of 146 
the TEWL recorded for the fully compromised barrier. Thus, three levels of barrier 147 
function impairment were studied: 20-40% (Intermediate “less” barrier), 60-80% 148 
(Intermediate “plus” barrier), and 100% (fully compromised barrier). 149 
2.3 Iontophoresis set-up 150 
Side-by-side two-compartment diffusion cells (active transport area = 0.78 cm2, 151 
volume = 3.3 mL) were used in all experiments. The skin was mounted between the 152 
two chambers with the epidermal side oriented towards the cathode compartment. 153 
The receptor chamber always held 154 mM sodium chloride solution (unbuffered, 154 
pH ~ 6). Prior to the start of the transport study, the skin was left for 30 minutes in 155 
contact with the donor vehicle without drug, and 154 mM sodium chloride in the 156 
receptor chamber. The compartments were then emptied and refilled with a donor 157 
solution containing sodium phenobarbital and with fresh receptor solution. Both 158 
compartments were magnetically stirred (Multipoint-6 stirrer, Thermo Scientific 159 
Variomag, Cole-Parmer, UK) throughout the experiment. A direct constant current of 160 
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0.4 mA (0.5 mA.cm-2) was delivered using Ag/AgCl electrodes and a power supply 161 
(KEPCO 1000M, Flushing, NY, USA). Hourly samples (0.5 mL) of the receptor phase 162 
were withdrawn for analysis and replaced with fresh receptor solution. Experiments, 163 
which compared phenobarbital iontophoretic delivery through different skin 164 
barriers, also monitored passive permeation (same donor solution) post-current 165 
termination. Separate passive diffusion controls (no current) through both intact and 166 
compromised skin were also performed. The details of the experiments performed 167 
are in Table 1. 168 
Another series of experiments examined the effect of iontophoresis on the 169 
passive permeability of intact skin to phenobarbital. Prior to the permeation study, 170 
and in the absence of phenobarbital (i.e., with a donor compartment containing 171 
water, pH 8.5, and receptor compartment containing unbuffered 154 mM NaCl), a 172 
0.4 mA current was applied for 5 hours. At this point, the current was terminated 173 
and the compartments were then emptied and refilled with a donor solution 174 
containing phenobarbital and with fresh receptor solution. Passive diffusion was 175 
then followed for 24 hours. To account for any effect of skin hydration during the 176 
pre-iontophoresis, the same experiment was repeated without application of current 177 
and with the donor and receptor compartments being filled with water and 154 mM 178 
NaCl, respectively. 179 
2.4 Phenobarbital and chloride analysis 180 
Quantification of phenobarbital was performed by high performance liquid 181 
chromatography with UV detection (215 nm). The method was modified from a 182 
previous publication (Sekkat, 2004b) and used a Jasco HPLC system (PU-980 pump 183 
with an AS-1595 autosampler, a UV-975 UV-VIS detector, and an Acclaim 120, C18 184 
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(150 x 4.6 mm, 5µm) reversed-phase column (Dionex, UK) which was thermostated 185 
at 30 °C). The mobile phase, pumped at 1 mL.min-1, consisted of phosphate buffer 186 
(0.067 M KH2PO4) and acetonitrile (70:30) and the pH was adjusted to 6 with NaOH.  187 
Chloride was analysed by ion chromatography with suppressed conductivity 188 
detection (Sylvestre, 2008) using a Dionex system (Sunnyvale, CA) comprising a GP-189 
50 gradient pump, an AS-50 autosampler and thermal compartment, and an ED-50 190 
electrochemical detector. The mobile phase, 35 mM NaOH, was pumped isocratically 191 
(1 mL.min-1 flow rate) through a Dionex IonPacTM AS16 (250 x 4 mm) column 192 
thermostated at 30⁰C and connected to a Dionex ASRS Ultra II suppressor (4 mm) set 193 
at a current of 90 mA. 194 
2.5 Data analysis and statistics 195 
Data analysis was performed using Graph Pad Prism V.5.00 (Graph Pad Software 196 
Inc., CA, USA). Unless otherwise stated, data are presented as the mean ± standard 197 
deviation. Transport fluxes were calculated as the amounts delivered during a 198 
permeation period divided by the length of that period. Statistical significance was 199 
set at p < 0.05. Comparisons made between different sets of data were assessed by 200 
either a two-tailed unpaired t-test (for 2 groups) or a one-way ANOVA (for > 2 201 
groups) followed by Tukey’s post-test. Comparison of fluxes at different times was 202 
assessed by repeated-measures ANOVA followed by Tukey’s post-test. 203 
The corrected transference number (tCOR,PHEN) of phenobarbital was computed 204 
according to Faraday’s law (Phipps, 1992): 205 
I
FzJ
t
PHEN,COR
PHEN

 ,  Equation 1 206 
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where, JCOR,PHEN is the corrected flux, I is the current intensity applied, F is faraday’s 207 
constant, and z the absolute value of the drug valence. Transference numbers were 208 
calculated from the corrected fluxes representing those observed after 5 hours 209 
iontophoresis (JPHEN) minus the passive diffusion rate 5 hours post-current 210 
termination. 211 
3. Results and discussion 212 
3.1 Passive diffusion across intact skin 213 
The passive diffusion of phenobarbital from a 50 mM aqueous drug solution (pH 214 
8.5) across (i) untreated skin, (ii) skin pre-treated with 0.4 mA current for 5 hours, 215 
and (iii) skin hydrated for 5 hours is shown in Figure 1 in terms of drug permeation as 216 
a function of time. The cumulative amounts transported (± SD) 24 hours post-drug 217 
application were: 91.7 ± 33.7, 415 ± 125, and 222 ± 35.5 nmol.cm-2 for untreated, 218 
pre-iontophoresed, and pre-hydrated skin, respectively. Passive diffusion across pre-219 
iontophoresed skin was significantly higher than through untreated (p < 0.01) and 220 
pre-hydrated (p < 0.05) skin. Increased permeability of skin previously exposed to 221 
direct current has been previously reported (Green, 1992). 222 
3.2 Iontophoretic delivery across intact skin 223 
The first donor solution tested was 50 mM sodium phenobarbital in water (pH 224 
8.5) where the drug (pKa = 7.3) (Merk Index, 2006) was ~93 % ionised. Cathodal 225 
iontophoresis resulted in drug delivery that was 385-fold higher than passive 226 
diffusion (Figure 2). After only 1 hour of current application, the phenobarbital flux 227 
was 222 ± 94.4 nmol.h-1 increasing to 387 ± 57.2 nmol.h-1 by 3 hours. At the end of 228 
the experiment (5 h), the flux was 341 ± 64.5 nmol.h-1. 229 
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A second series of iontophoresis experiments compared anodal versus cathodal 230 
delivery of phenobarbital at pH 7.4 where phenobarbital exists in essentially equal 231 
concentrations of the ionized and unionized forms. The former, of course, can be 232 
delivered from the cathode by electro-repulsion, while the latter may be transported 233 
from the anode by electro-osmosis. A donor concentration of 15 mM was used 234 
because of phenobarbital’s lower solubility at this pH. Chloride ions are required to 235 
ensure adequate electrochemistry at the anode, and 50 mM NaCl was therefore 236 
added to both the cathodal and anodal solutions. Cathodal iontophoresis (Figure 3) 237 
was much more efficient than anodal. When the contribution of passive diffusion 238 
was taken into account, the corrected cathodal and anodal fluxes at 5 hours were 239 
42.4 ± 13.3 and 7.1 ± 3.8 nmol.h-1, respectively. These results are in good agreement 240 
with previous data (e.g., for 5-fluorouracil (Merino, 1999) and for phenytoin 241 
(Leboulanger,2004)) which showed that electromigration is a much more efficient 242 
transport mechanism than electroosmosis. The reduced cathodal delivery observed 243 
here relative to that observed at pH 8.5 is explained by the lower concentration of 244 
ionized drug employed, decreasing from 46.3 mM (~93 % of 50 mM) to 7.5 mM 245 
(~50% of 15 mM) and by the presence of 50 mM competing chloride ions in the pH 246 
7.4 experiment. 247 
The effect of co-ion competition on cathodal delivery by electro-repulsion was 248 
then investigated. In an initial experiment, a 15 mM PHEN solution, the pH of which 249 
had been adjusted to 7.4 with HCl was used, resulting in introduction of Cl- at a 250 
concentration of approximately 6 mM. As this represents a lower level of chloride 251 
ions compared to the earlier experiment, an increase in tPHEN and PHEN flux might 252 
have been expected. However, the concentration of competing chloride increases 253 
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above the initial 6 mM during the experiment because of the gradual release of Cl- 254 
from the cathode as the electrochemistry reduces AgCl to Ag (Figure 4). This implies 255 
that transport number of the drug would decrease as the experiment proceeds. 256 
A subsequent experiment attempted to mitigate the impact of chloride 257 
accumulation on the cathodal flux of PHEN by refreshing the donor solution every 258 
hour. In a related experiment, 10 mM HEPES was employed as a buffer for the 15 259 
mM sodium phenobarbital donor solution. This provided good buffer capacity 260 
without requiring any adjustment to pH 7.4 with HCl (thereby avoiding the 261 
introduction of extra chloride ions). Again, to counter the build-up of chloride ions 262 
released from the electrode, the donor solution was refreshed hourly. It was 263 
calculated that Cl- release from the cathode would contribute (in the diffusion cells 264 
used) a concentration of 4.5 mM for every hour of 0.4 mA current applied. Figure 4 265 
illustrates the anticipated evolution of chloride concentration in the donor solution 266 
as a function of time under the experimental conditions employed. The predicted 267 
values agree closely with those measured experimentally by ion chromatography.  268 
The PHEN fluxes were inversely related to the Cl- concentration present in the 269 
donor solution after 5 hours of current application. The greater the co-ion 270 
competition with PHEN, the lower the drug transport (Figure 4). Chloride 271 
accumulation in the cathodal chamber plays a key role in the iontophoretic delivery 272 
of negatively-charged drugs as previously demonstrated for dexamethasone 273 
phosphate (Sylvestre, J.P., 2008a. 2008b) and needs careful optimization. 274 
The transport number of phenobarbital (tPHEN) was linearly proportional (r
2  275 
0.80) to the drug’s molar fraction in the vehicle (Figure 5). Following the principles 276 
demonstrated by Mudry et al. (2006) for cation electrotransport, and assuming their 277 
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validity for the anionic PHEN, the maximum transport number of the drug at pH 7.4, 278 
i.e., in the absence of competing co-ions, is estimated to be 0.035 (determined by 279 
substitution of XPHEN=1 in the linear regression equation given in Figure 5). 280 
3.3 Permeation across compromised skin 281 
The objective of this part of study was to examine the permeation of 282 
phenobarbital across barriers representative of those found in premature neonates 283 
whose stratum corneum may be absent or not fully developed. Three impaired levels 284 
of barrier function were evaluated against intact skin for passive as well as 285 
iontophoretic delivery of the drug. The average TEWL measurements (g.m-2.h-1) 286 
across the different skin barriers were as follows: 11 ± 1, 44 ± 10, 114 ± 20, and 158 ± 287 
25, respectively, for intact, intermediate “less”(20 – 40 %), intermediate “plus” (60 – 288 
80 %), and fully compromised skin. The TEWL values were significantly higher than 289 
those reported in previous studies, which validated the usefulness of serially 290 
stripped pig skin as a model for that of the developing neonate and subsequently 291 
employed the approach to predict the transdermal permeation of phenobarbital, 292 
caffeine, and lidocaine (Sekkat 2004a, 2004b). The discrepancy is between a factor of 293 
two and four and is probably due to the different TEWL devices employed in the two 294 
studies (i.e., the study closed-chamber evaporimeter (AquaFlux AF102, Biox) used 295 
here versus an open-chamber instrument (EP1, Servomed) used before (Farahmand, 296 
2009, Imhof 2009). Other factors may have played a part, such as the number of 297 
tape-strips used to remove the stratum corneum, and the pressure with which the 298 
tapes were applied (Escobar-Chavez, 2008, Rubio et al., 2011). 299 
Passive diffusion of phenobarbital increased dramatically as the stratum 300 
corneum was progressively compromised (Figure 6). The flux at 5 hours through 301 
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intact skin was only 0.9 ± 0.2 nmol.h-1, but increased to 810 ± 251 nmol.h-1 for fully 302 
compromised skin. Transport through barriers with intermediate levels of 303 
impairment levels fell between these two extremes: 31 ± 12 nmol.h-1 and 561 ± 179 304 
nmol.h-1 for 20-40 % and 60-80 % of barrier disruption, respectively. 305 
Previously, a similar phenobarbital permeation rate across intact full-thickness 306 
pig ear skin was measured when the drug was delivered from a saturated solution of 307 
the unionised drug (4.3 mM) at pH 5 (Sekkat, 2004b). Permeation across fully 308 
compromised skin was ~30 times higher than that through the intact barrier. In 309 
contrast, the enhancement factor observed in this work was more than 900-fold due, 310 
at least in part, to the fact that most of the drug was ionised (~3.7 mM unionized) 311 
and hence in a less favourable form for passive permeation. With progressive 312 
removal of the stratum corneum, the ionised and neutral forms of phenobarbital 313 
permeated through the less-resistant skin barrier at much higher rates. Similar 314 
behaviour has been seen for 5-fluorouracil (Fang, 2004), with removal of the stratum 315 
corneum leading to an increase in passive diffusion from < 0.03 µmol.cm-2 in 6 hours 316 
to approximately 17 µmol.cm-2 a difference of more than 550-fold. 317 
Figure 6 summarizes the iontophoretic delivery of phenobarbital through 318 
compromised skin barriers. The fluxes measured during 5 hours of iontophoresis (0.4 319 
mA) application followed by 5 hours of passive diffusion are shown. Table 2 presents 320 
the fluxes during the last hour of the permeation studies. The iontophoretic fluxes 321 
observed increased with the level of skin impairment but complete removal of the 322 
stratum corneum only resulted in a 3.6-fold enhancement relative to intact skin 323 
(Table 2). When the contribution of passive diffusion is taken into account, the 324 
corrected iontophoretic fluxes, and the corresponding tPHEN, are very similar for all 325 
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skin barriers tested (Table 2). In fact, no significant differences were found between 326 
these values. It follows that while iontophoretic flux remained constant and 327 
independent of the skin barrier function, passive diffusion increased remarkably as 328 
the skin was progressively compromised and eventually overshadowed any benefits 329 
from iontophoresis. Qualitatively, these results are consistent with those reported 330 
for lidocaine hydrochloride (Sekkat, 2004b), for which the total iontophoretic 331 
delivery was practically the same across intact (1.8 ± 0.5 mg.cm-2) and tape-stripped 332 
skin (1.9±0.3 mg.cm-2). In contrast, the passive permeability of lidocaine HCL 333 
increased from 7x10-4 ± 4x10-4 mg.cm-2 across intact skin to 0.1±0.07 mg.cm-2 334 
through a fully tape-stripped barrier. Quantitatively, however, the difference 335 
between the behaviour of lidocaine and phenobarbital is important. In the case of 336 
lidocaine, the passive diffusion of the drug even across fully-compromised skin is still 337 
an order of magnitude smaller than iontophoretic delivery; electrotransport can be 338 
used, therefore, to control drug input independent of the status of skin barrier 339 
function. For phenobarbital, on the other hand, passive transport increases 340 
significantly with progressive derangement of the barrier, ultimately overwhelming 341 
iontophoretic delivery, which is no longer able to exercise control over the 342 
absorption of the drug when the stratum corneum has been compromised. 343 
Finally, a summary of the passive and iontophoretic transport of phenobarbital 344 
as a function of TEWL (reflecting barriers of varying competence) is shown in Figure 345 
7. The slopes of the linear regressions through the passive and iontophoretic fluxes 346 
are not significantly different. This emphasizes the point made above that, once the 347 
function of the stratum corneum has been undermined (>50%), the passive transport 348 
 16 
of phenobarbital exceeds that due to iontophoresis and dominates the transdermal 349 
delivery of the drug.  350 
3.4 Feasibility of phenobarbital transdermal delivery  351 
Phenobarbital is used for different purposes in neonatal and paediatric patients. 352 
Examination of the doses used for different indications (BNF for children 2011, Bio, 353 
2011; Finnegan, 2005; Osborn, 2010) quickly reveals that the transdermal route 354 
would not provide the initially large doses required to treat status epilepticus (20 355 
mg.kg-1 for neonates) or the loading doses required for epilepsy and neonatal 356 
abstinence syndrome. However, the maintenance doses for status epilepticus are 357 
much lower: 2.5-5 mg.kg-1 once or twice a day for both neonates and children aged 1 358 
month to 12 years (BNF for children 2011). For epilepsy, the maintenance doses are 359 
2.5-5 mg.kg-1.day-1 and up to 2.5-8 mg.kg-1.day-1 for neonates and children (1 month-360 
12 years) respectively, (BNF for children 2011). The maintenance doses 361 
recommended for treating neonatal withdrawal symptoms fall in the range 2-10 362 
mg.kg-1.day-1 (Bio, 2011; Finnegan, 2005; Osborn, 2010). The phenobarbital doses 363 
required for any of the indications mentioned in children older than 12 years are too 364 
large for transdermal administration. 365 
Table 3 calculates the passive and iontophoretic patch sizes required to deliver 366 
maintenance doses between 2 and 10 mg.kg-1.day-1 (0.3 to 1.6 µmol.kg
-1.h-1) i.e., 367 
amounts spanning the three potential applications of phenobarbital discussed 368 
above. The fluxes used in these calculations were those measured when the donor 369 
solution was 50 mM of drug in water at pH 8.5. 370 
Assuming a quantitative in vitro-in vivo correlation, transdermal delivery of 371 
phenobarbital to neonates (including premature and full-term) appears feasible. 372 
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Indeed, passive would be sufficient for premature neonates with significantly 373 
immature skin. However, as the skin barrier matures, iontophoresis would become 374 
progressively more effective in providing desirable rates of delivery while keeping 375 
patch size reasonable (Table 3). For safety reasons, and the variable degree of barrier 376 
immaturity in the premature neonate, transdermal patches with rate-limiting 377 
membranes may be preferable, to ensure rate-control and to avoid potential 378 
toxicity. A key challenge with premature neonates is to compensate the rate of drug 379 
delivery for the degree of barrier maturation. 380 
Premature neonates of only 23-25 weeks gestational age may require more 381 
than 4 weeks to develop a full functional stratum corneum (Kalia, 1998); whereas 382 
those born at 32 weeks of more have a barrier function that is close to fully 383 
functional. To treat this “moving target” would require passive patches in a variety of 384 
sizes (and even designs, e.g., rate-controlling versus matrix); alternatively 385 
iontophoresis might prove more useful in that the intensity and duration of current 386 
can be “tuned” to provide the required drug input. This flexibility in dosage form 387 
design and operation would rely, of course, on the application of TEWL 388 
measurements to pinpoint barrier function status in the patient (Fluhr, 2006, Levin, 389 
2005). 390 
Table 3 also shows that iontophoresis may deliver therapeutic amounts of 391 
phenobarbital to infants of 1 month or more to young children. For older children, 392 
however, phenobarbital transdermal delivery may not be useful because the 393 
requisite patch area becomes too large. For example, the patch sizes required to 394 
deliver 2-10 mg.kg-1.day-1 would be 4-20 cm
2, 6-32 cm2, and 12-64 cm2 for paediatric 395 
patients weighing 3, 5 and a 10 kg, respectively. 396 
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Ultimately, in vivo studies will be required to demonstrate that the in vitro-in 397 
vivo correlation assumed is valid and to examine the effect of current application 398 
and other formulation variables (such as pH) on the skin of infants and premature 399 
neonates.  400 
4. Conclusions 401 
This study demonstrated that cathodal iontophoresis of phenobarbital through 402 
intact skin is more efficient than anodal iontophoresis and passive diffusion. 403 
Competition from anions present in the donor formulation must be minimized to 404 
optimize phenobarbital delivery. The results suggest that both passive and 405 
iontophoretic delivery of this drug to premature neonatal and paediatric patients 406 
may, in some circumstances, be feasible and attractive. Of course, the costs 407 
associated with the development and use of such new transdermal systems must be 408 
carefully balanced against their potential to provide an improved and better-409 
tolerated therapy.    410 
 411 
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 493 
Table 1: Experiments performed to characterise phenobarbital transdermal 494 
delivery through intact, pretreated and impaired skin. 495 
 496 
497 
Skin barrier Donor 
PHEN 
(mM) 
Experiment settings and duration n 
Intact 
Water (pH 8.5) 50 
(1) Cathodal iontophoresis (5h),  
then passive diffusion (5h) 
3 
Passive diffusion (24h) 3 
50 mM NaCl (pH 7.4) 15 
(2) Cathodal iontophoresis (5h) 4 
Anodal iontophoresis (5h) 4 
Passive diffusion (24h) 6 
Water (pH 7.4) 15 
(3) Cathodal iontophoresis (5h) 6 
(4) Cathodal iontophoresis (5h). 
Donor solution exchanged hourly
 
5 
10 mM HEPES 
(pH 7.4) 
15 
(5) Cathodal iontophoresis (5h). 
Donor solution exchanged hourly 
5 
Pre-treated Water (pH 8.5) 50 
Pre-treatment: 0.4 mA for 5 h 
followed by passive diffusion (24h) 4 
 Pre-treatment: hydration for 5 h 
followed by passive diffusion (24h) 
Impaired: 
20-40 % 
60-80 % 
100 % 
Water (pH 8.5) 50 
Cathodal iontophoresis (5h),  
then passive diffusion (5h) 
3-5 
Passive diffusion (24h) 3-5 
 24 
Table 2: Fluxes of phenobarbital (µmol.h-1, mean ± SD), through differentially-498 
impaired skin barriers, after 5 hours of iontophoresis, and after a further 5 hours of 499 
passive diffusion post-current application. The corrected values (JCOR,PHEN) are the 500 
differences between the measurements in the first two columns and are used to 501 
calculate the transport number (tPHEN) shown. 502 
 503 
Skin barrier 
Iontophoresis 
JPHEN
 
Passive post- 
iontophoresis 
Corrected 
JCOR,PHEN 
102 x tPHEN 
Intact 0.34 ± 0.06 0.05 ± 0.01 0.30 ± 0.07 2.0 ± 0.4 
Intermediate “less” 0.60 ± 0.09 0.24 ± 0.08 0.35 ± 0.08 2.4 ± 0.5 
Intermediate “plus” 0.94 ± 0.27 0.63 ± 0.31 0.31 ± 0.09 2.1 ± 0.6 
Fully compromised 1.23 ± 0.32 0.92 ± 0.25 0.31 ± 0.08 2.1 ± 0.5 
 504 
 505 
 506 
 507 
508 
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Table 3: Estimated patch sizes required to deliver maintenance doses of 509 
phenobarbital assuming that the in vitro fluxes determined in this work are reflective 510 
of those achievable in vivo. 511 
 512 
Skin type: Intact 
Intermediate 
“less” 
Intermediate 
“plus” 
Fully 
compromised 
Passive 
In vitro flux (µmol.h
-1
.cm
-2
)
 a
 Negligible 0.1 ± 0.02 0.8 ± 0.2 1.1 ± 0.4 
Patch size required (cm
2
.kg
-1
)  3 – 16 0.4 – 2 0.3 – 1.5 
Iontophoresis (0.5 mA.cm
-2
) 
In vitro flux (µmol.h
-1
.cm
-2
) 
a
 0.5 ± 0.1 0.7 ± 0.1 1.2 ± 0.4 1.5 ± 0.4 
Area per electrode (cm
2
.kg
-1
) 0.6 – 3.2  0.4 – 2.3  
 
0.25 – 1.3 0.2 – 1.1 
Total patch size (cm
2
.kg
-1
) 
b
 1.2 – 6.4 0.8 – 4.6 0.5 – 2.6 0.4 – 2.2 
 513 
a Fluxes are the average values measured after 2 – 5 hours of iontophoresis (0.5 mA.cm-2) or 514 
passive diffusion. 515 
b Assuming that the areas occupied by the anodal and cathodal electrode formulations are 516 
the same. 517 
 518 
519 
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 520 
Figure legends 521 
 522 
Figure 1: Passive diffusion of phenobarbital through intact pig skin. Pre-523 
treatment either involved 5 hours direct current at 0.4 mA or 5 hours hydration 524 
without current. Phenobarbital was not present in the pre-treatment periods. Data 525 
are represented as the mean ± SD. 526 
 527 
 528 
Figure 2: Passive and iontophoretic transdermal fluxes (mean ± SD) of 529 
phenobarbital after 5 hours from a 50 mM drug solution. 530 
 531 
 532 
Figure 3: Anodal and cathodal iontophoresis of phenobarbital when delivered 533 
from a 15 mM drug solution at pH 7.4. The passive diffusion control is also shown. 534 
Data points are represented as mean ± SD. 535 
 536 
 537 
Figure 4: Left panel: Estimated donor concentration of chloride ions (dashed 538 
lines) and the corresponding measurements (symbols, mean ± SD) for experiments 3 539 
(), 4 (), and 5 () as indicated in Table 1. Right panel: Cathodal delivery of 540 
phenobarbital from different donor solutions (pH 7.4) containing various amounts of 541 
competing co-ions (experiments 2-5 in Table 1). The flux values (mean ± SD) were 542 
determined after 5 hours of iontophoresis (0.4 mA). 543 
 27 
Figure 5: Transport number of phenobarbital (tPHEN, mean ± SD) as a function of 544 
molar fraction (XPHEN). Values of the latter parameter were calculated from the 545 
concentrations of phenobarbital, HEPES, and chloride. The sources of Cl- included 546 
NaCl (used as background electrolyte), HCl (used to adjust the donor solution pH), 547 
and the electrode electrochemical reaction. Data expressed by the same symbol and 548 
number represent the experimental condition as identified in Table 1. The dashed 549 
line is the linear regression through all data points except those obtained with 550 
HEPES: tPHEN = 0.002 (±0.001) + 0.033 (±0.002) XPHEN, (r
2 > 0.8). 551 
 552 
 553 
Figure 6: Passive (left panel) and iontophoretic (right panel) transport (mean ± 554 
SD) of phenobarbital delivered from a 50 mM drug solution through intact and 555 
compromised skin barriers. The right panel also shows the passive diffusion of 556 
phenobarbital post-current termination at 5 hours. 557 
 558 
 559 
Figure 7: Total passive and iontophoretic fluxes of phenobarbital as a function 560 
of TEWL across skin barriers of different competencies. Open symbols refer to 561 
passive diffusion alone; filled symbols reflect the total drug flux when an 562 
iontophoretic current is applied. Intact, intermediate “less” (20–40 %), intermediate 563 
“plus” (60–80 %) and fully compromised skin barriers are respectively symbolized by 564 
diamonds, triangles, circles, and squares. Linear regressions through the passive and 565 
iontophoretic results were:  JPassive = -156 (±97) + 8.3(±1.1) TEW and Jionto = 372 566 
(±101) + 7.0(±0.9) TEWL, with r2 values of 0.85 and 0.82, respectively. 567 
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